- In a placebo-controlled trial, cord stem cells lowered HbA1c and insulin needs more than placebo.
- The cells seem to work on the inflammation that makes tissue deaf to insulin, not on new beta cells.
- Every body responds at its own pace, and your own doctor keeps leading your diabetes care.
You know the routine by heart. The finger prick, the pill organizer, the appointment where the HbA1c comes back a little higher and the dose goes up again. You are doing the work, and the numbers still drift.
Umbilical cord mesenchymal stem cells are one of the most studied new ideas in type 2 diabetes. There is real, published human data now, including trials with a placebo group. Here is what those studies found, in plain words.
Why does the sugar keep climbing?
In type 2 diabetes the pancreas usually still makes insulin. The problem is that muscles, liver and fat stop responding to it well. That is insulin resistance, and a low, constant inflammation keeps feeding it.
Imagine insulin as a key that still fits the lock, but the lock is gummed up. The pancreas answers by making more keys, and over years it gets tired. Medication helps you push the door open; it does not clean the lock.
That is why researchers got interested in mesenchymal stem cells. They are known for their immunomodulatory effect: they release signals that may turn down chronic inflammation. The idea is not to replace your pancreas, but to take some weight off it.
What did the trials actually find?
The strongest single study is a double-blind, placebo-controlled phase II trial published in 2022. Ninety-one adults with type 2 diabetes received three intravenous infusions of umbilical cord MSCs or a placebo, four weeks apart, and were followed for 48 weeks.
- HbA1c, your three-month blood sugar average, fell by 1.31 points with the cells, versus 0.63 with placebo
- Insulin doses dropped more in the cell group
- About one in five treated patients reached the combined goal of HbA1c under 7% while halving their insulin, versus fewer than one in twenty on placebo
- No major treatment-related adverse events were reported
A second trial from the same team, using continuous glucose monitors, found more time in range in the cell group at 9 and 48 weeks: steadier days, fewer highs.
How big is the bigger picture?
A 2025 umbrella review pooled 17 systematic reviews and meta-analyses covering more than 8,000 patients. Across them, MSC therapy lowered HbA1c by up to about 1.45 points and reduced insulin needs, with the clearest effect in type 2. Side effects were mostly mild.
The same review found that Wharton’s jelly MSCs, from the tissue of the umbilical cord, performed better than MSCs from umbilical cord blood. Same cord, different tissue, different results.
How should you read these results?
These trials are encouraging, and research is growing. Every body responds at its own pace, which is why your markers are measured before and after.
Diet, movement and your usual medication still matter. The cells are studied as a partner to good diabetes care.
- Bring your last HbA1c, glucose and insulin numbers; they are the starting line for your plan.
- Expect gradual change measured in lab results, and keep your doctor at home in charge of your medication.
- Send your numbers on WhatsApp for a free evaluation, with your plan and price in writing and no commitment.
Several randomized trials and a large umbrella review suggest that mesenchymal stem cells may lower HbA1c and insulin needs in type 2 diabetes, with a reassuring safety record. Research is growing, and longer studies keep building on these results.
- Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial · Stem Cell Research & Therapy, 2022
- Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes Assessed by Retrospective Continuous Glucose Monitoring · Stem Cells Translational Medicine, 2023
- Mesenchymal stem cell therapy for diabetes: An umbrella review · Tissue and Cell, 2025
Questions
Can I stop insulin or my pills after treatment?
Never on your own. In studies some patients needed less insulin, but any change to your medication is decided by your doctor, based on your numbers.
How long does the protocol take in Medellín?
Three days, with the hotel in the same building as the treatment center.
How do you make sure it is safe for me?
Every IV protocol starts with blood work and cancer markers, for your safety.
When would I see a change?
Every body responds at its own pace. In the trials, changes in HbA1c were measured over weeks to months. Your doctor follows the same markers before and after.
Is stem cell therapy approved by the FDA?
Stem cell therapy is not approved by the FDA, but in Colombia it is legal.